单克隆抗体作为抗基孔肯雅病毒的预防和治疗药物
Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
作者信息
Clayton April M
机构信息
Office of Global Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
出版信息
J Infect Dis. 2016 Dec 15;214(suppl 5):S506-S509. doi: 10.1093/infdis/jiw324.
Abstract
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for considerable epidemics worldwide and recently emerged in the Americas in 2013. CHIKV may cause long-lasting arthralgia after acute infection. With currently no licensed vaccines or antivirals, the design of effective therapies to prevent or treat CHIKV infection is of utmost importance and will be facilitated by increased understanding of the dynamics of chikungunya. In this article, monoclonal antibodies against CHIKV as viable prophylactic and therapeutic agents will be discussed.
摘要
基孔肯雅病毒（CHIKV）是一种由蚊子传播的甲病毒，在全球范围内引发了相当大规模的疫情，并且于2013年在美洲首次出现。CHIKV急性感染后可能导致持续时间较长的关节痛。由于目前尚无获批的疫苗或抗病毒药物，设计有效的预防或治疗CHIKV感染的疗法至关重要，而对基孔肯雅热动态的深入了解将有助于实现这一目标。在本文中，将讨论针对CHIKV的单克隆抗体作为可行的预防和治疗药物的情况。
相似文献
1
Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.单克隆抗体作为抗基孔肯雅病毒的预防和治疗药物
J Infect Dis. 2016 Dec 15;214(suppl 5):S506-S509. doi: 10.1093/infdis/jiw324.
2
Development of Vaccines for Chikungunya Fever.基孔肯雅热疫苗的研发
J Infect Dis. 2016 Dec 15;214(suppl 5):S488-S496. doi: 10.1093/infdis/jiw271.
3
A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.一种包裹脂质的 mRNA 编码了一种强效中和的人源单克隆抗体，可预防基孔肯雅热感染。
Sci Immunol. 2019 May 17;4(35). doi: 10.1126/sciimmunol.aaw6647.
4
Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.抗基孔肯雅病毒单克隆抗体抑制病毒融合和释放。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00252-20.
5
Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.抗体介导的增强作用会加重基孔肯雅病毒感染和疾病严重程度。
Sci Rep. 2018 Jan 30;8(1):1860. doi: 10.1038/s41598-018-20305-4.
6
Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.具有抗基孔肯雅病毒治疗活性的广谱和超强效人单克隆抗体的分离与鉴定
Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009.
7
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.基孔肯雅病毒的全灭活疫苗和病毒样颗粒疫苗策略
J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499. doi: 10.1093/infdis/jiw352.
8
A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.一种靶向E2蛋白上N218表位的强效中和性IgM单克隆抗体可预防基孔肯雅病毒发病。
MAbs. 2015;7(6):1178-94. doi: 10.1080/19420862.2015.1083664. Epub 2015 Aug 25.
9
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.基孔肯雅病毒包膜三聚体外侧表位残基的暴露决定抗体中和效力。
J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.
10
Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.基于抗体的治疗干预：应对基孔肯雅病毒感染的可能策略。
Appl Microbiol Biotechnol. 2020 Apr;104(8):3209-3228. doi: 10.1007/s00253-020-10437-x. Epub 2020 Feb 19.
引用本文的文献
1
Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity.异源 DNA 初免-亚单位蛋白加强免疫基孔肯雅病毒 E2 诱导中和抗体和细胞介导免疫。
Int J Mol Sci. 2023 Jun 23;24(13):10517. doi: 10.3390/ijms241310517.
2
Evolution and immunopathology of chikungunya virus informs therapeutic development.基孔肯雅热病毒的进化和免疫病理学为治疗方法的开发提供了信息。
Dis Model Mech. 2023 Apr 1;16(4). doi: 10.1242/dmm.049804. Epub 2023 Apr 4.
3
Cooperative Chikungunya Virus Membrane Fusion and Its Substoichiometric Inhibition by CHK-152 Antibody.协同型基孔肯雅病毒膜融合及其对 CHK-152 抗体的亚化学计量抑制。
Viruses. 2022 Jan 28;14(2):270. doi: 10.3390/v14020270.
4
Expression, Purification, and Refolding of Chikungunya Virus Full-Length Envelope E2 Protein along with B-Cell and T-Cell Epitope Analyses Using Immuno-Informatics Approaches.基孔肯雅病毒全长包膜E2蛋白的表达、纯化与复性以及利用免疫信息学方法进行B细胞和T细胞表位分析
ACS Omega. 2022 Jan 14;7(4):3491-3513. doi: 10.1021/acsomega.1c05975. eCollection 2022 Feb 1.
5
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.一项针对脂质包裹的编码具有中和抗基孔肯雅病毒活性的单克隆抗体的 mRNA 的 1 期临床试验。
Nat Med. 2021 Dec;27(12):2224-2233. doi: 10.1038/s41591-021-01573-6. Epub 2021 Dec 9.
6
Prophylactic strategies to control chikungunya virus infection.控制基孔肯雅病毒感染的预防策略。
Virus Genes. 2021 Apr;57(2):133-150. doi: 10.1007/s11262-020-01820-x. Epub 2021 Feb 15.
7
Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody.一种广泛中和抗基孔肯雅病毒单域抗体的稳定化
Front Med (Lausanne). 2021 Jan 28;8:626028. doi: 10.3389/fmed.2021.626028. eCollection 2021.
8
Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.基于抗体的治疗干预：应对基孔肯雅病毒感染的可能策略。
Appl Microbiol Biotechnol. 2020 Apr;104(8):3209-3228. doi: 10.1007/s00253-020-10437-x. Epub 2020 Feb 19.
9
Recent development in the strategies projected for chikungunya vaccine in humans.针对人类基孔肯雅热疫苗的策略的最新进展。
Drug Des Devel Ther. 2018 Dec 10;12:4195-4206. doi: 10.2147/DDDT.S181574. eCollection 2018.
10
Cellular and Molecular Immune Response to Chikungunya Virus Infection.细胞和分子免疫对基孔肯雅病毒感染的反应。
Front Cell Infect Microbiol. 2018 Oct 10;8:345. doi: 10.3389/fcimb.2018.00345. eCollection 2018.
本文引用的文献
1
Potent Antibody Protection against an Emerging Alphavirus Threat.强效抗体对新兴甲病毒威胁的保护作用。
Cell. 2015 Nov 19;163(5):1053-1054. doi: 10.1016/j.cell.2015.11.006.
2
Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.广谱中和性甲病毒抗体结合 E2 上的一个表位，并抑制进入和离开。
Cell. 2015 Nov 19;163(5):1095-1107. doi: 10.1016/j.cell.2015.10.050. Epub 2015 Nov 6.
3
Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission.与人类抗体复合的基孔肯雅病毒样颗粒的结构研究：中和作用与细胞间传播
J Virol. 2015 Nov 4;90(3):1169-77. doi: 10.1128/JVI.02364-15. Print 2016 Feb 1.
4
Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.登革病毒中和作用的基因型差异可由一个调节病毒呼吸的单氨基酸突变来解释。
mBio. 2015 Nov 3;6(6):e01559-15. doi: 10.1128/mBio.01559-15.
5
Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.冷冻电镜结构阐明了具有治疗活性的抗基孔肯雅病毒人单克隆抗体的中和机制。
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13898-903. doi: 10.1073/pnas.1515558112. Epub 2015 Oct 26.
6
Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses.确定E2结构域在甲病毒中和及保护性免疫反应中的作用。
PLoS Negl Trop Dis. 2015 Oct 16;9(10):e0004163. doi: 10.1371/journal.pntd.0004163. eCollection 2015.
7
Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.具有抗基孔肯雅病毒治疗活性的广谱和超强效人单克隆抗体的分离与鉴定
Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009.
8
Chikungunya: Evolutionary history and recent epidemic spread.基孔肯雅热：进化史与近期的流行传播。
Antiviral Res. 2015 Aug;120:32-9. doi: 10.1016/j.antiviral.2015.04.016. Epub 2015 May 12.
9
Therapeutics and vaccines against chikungunya virus.针对基孔肯雅病毒的治疗方法和疫苗。
Vector Borne Zoonotic Dis. 2015 Apr;15(4):250-7. doi: 10.1089/vbz.2014.1681.
10
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.震动、摇晃与滚动：黄病毒颗粒动力学对其与宿主相互作用的影响
Virology. 2015 May;479-480:508-17. doi: 10.1016/j.virol.2015.03.025. Epub 2015 Mar 30.
Zotero 插件